Skip to content
2000
Volume 26, Issue 1
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Tumor-infiltrating immune cells (TIICs) have been identified as critical components in the development of cancer drug resistance. This review aims to discuss the various types of TIICs, such as macrophages and T cells, that have been linked to cancer drug resistance. Furthermore, we explore the mechanisms by which TIICs contribute to drug resistance and how these mechanisms may differ across various tumor types. Additionally, we examine the potential of immune checkpoint inhibitors in combination with traditional cancer therapies as a strategy to overcome TIIC-mediated cancer drug resistance. In conclusion, this review provides an in-depth analysis of the current knowledge on the role of TIICs in cancer drug resistance and highlights potential avenues for future research to develop more effective treatment strategies. The findings presented in this review emphasize the importance of understanding the complex interactions between cancer cells and the immune system in order to develop novel therapeutic approaches that can overcome TIIC-mediated cancer drug resistance.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206365310250310081445
2025-03-24
2026-03-01

  • From This Site

    /content/journals/acamc/10.2174/0118715206365310250310081445
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HanahanD. WeinbergR.A. Hallmarks of cancer: The next generation.Cell2011144564667410.1016/j.cell.2011.02.013 21376230
     [Google Scholar]
  2. KalluriR. ZeisbergM. Fibroblasts in cancer.Nat. Rev. Cancer20066539240110.1038/nrc1877 16572188
     [Google Scholar]
  3. SahranavardT. MehrabadiS. PouraliG. MaftoohM. AkbarzadeH. HassanianS.M. MobarhanM.G. FernsG.A. KhazaeiM. AvanA. The potential therapeutic applications of CRISPR/Cas9 in colorectal cancer.Curr. Med. Chem.202431355768577810.2174/0929867331666230915103707 37724673
     [Google Scholar]
  4. MantovaniA. SicaA. Macrophages, innate immunity and cancer: Balance, tolerance, and diversity.Curr. Opin. Immunol.201022223123710.1016/j.coi.2010.01.009 20144856
     [Google Scholar]
  5. MahoneyK.M. RennertP.D. FreemanG.J. Combination cancer immunotherapy and new immunomodulatory targets.Nat. Rev. Drug Discov.201514856158410.1038/nrd4591 26228759
     [Google Scholar]
  6. Stokic-TrticaV. DiefenbachA. KloseC.S.N. NK cell development in times of innate lymphoid cell diversity.Front. Immunol.20201181310.3389/fimmu.2020.00813 32733432
     [Google Scholar]
  7. MarmontiE. Oliva-RamirezJ. HaymakerC. Dendritic cells: The long and evolving road towards successful targetability in cancer.Cells20221119302810.3390/cells11193028 36230990
     [Google Scholar]
  8. BronteV. BrandauS. ChenS.H. ColomboM.P. FreyA.B. GretenT.F. MandruzzatoS. MurrayP.J. OchoaA. Ostrand-RosenbergS. RodriguezP.C. SicaA. UmanskyV. VonderheideR.H. GabrilovichD.I. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.Nat. Commun.2016711215010.1038/ncomms12150 27381735
     [Google Scholar]
  9. TiwariA. OraveczT. DillonL.A. ItalianoA. AudolyL. FridmanW.H. CliftonG.T. Towards a consensus definition of immune exclusion in cancer.Front. Immunol.202314108488710.3389/fimmu.2023.1084887 37033994
     [Google Scholar]
  10. HaoN.B. LüM.H. FanY.H. CaoY.L. ZhangZ.R. YangS.M. Macrophages in tumor microenvironments and the progression of tumors.Clin. Dev. Immunol.2012201211110.1155/2012/948098 22778768
     [Google Scholar]
  11. BaratiS. SaffarH. MehrabadiS. AvanA. The circadian clock as a potential biomarker and therapeutic target in gastrointestinal cancers.Curr. Pharm. Des.202430231804181110.2174/0113816128302762240515054444 38798218
     [Google Scholar]
  12. ChenY. SongY. DuW. GongL. ChangH. ZouZ. Tumor-associated macrophages: An accomplice in solid tumor progression.J. Biomed. Sci.20192617810.1186/s12929‑019‑0568‑z 31629410
     [Google Scholar]
  13. Pilotto HemingC. MuriithiW. MachariaW.L. N FilhoP. Moura-Neto, V.; Aran, V. P-glycoprotein and cancer: What do we currently know?Heliyon2022810e1117110.1016/j.heliyon.2022.e11171 36325145
     [Google Scholar]
  14. YousefiH. MomenyM. GhaffariS.H. ParsanejadN. PoursheikhaniA. JavadikoosheshS. IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer.Tumori20191051849110.1177/0300891618784790 30021477
     [Google Scholar]
  15. XiaoM. HeJ. YinL. ChenX. ZuX. ShenY. Tumor-associated macrophages: Critical players in drug resistance of breast cancer.Front. Immunol.20211279942810.3389/fimmu.2021.799428 34992609
     [Google Scholar]
  16. YangC. HeL. HeP. LiuY. WangW. HeY. DuY. GaoF. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway.Med. Oncol.20153221410.1007/s12032‑014‑0352‑6 25572805
     [Google Scholar]
  17. DongX. SunR. WangJ. YuS. CuiJ. GuoZ. PanX. SunJ. YangJ. PanL.L. Glutathione S-transferases P1-mediated interleukin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer.Biochem. Pharmacol.202018211428910.1016/j.bcp.2020.114289 33080187
     [Google Scholar]
  18. GuoY. AshrafizadehM. TambuwalaM.M. RenJ. OriveG. YuG. P-glycoprotein (P-gp)-driven cancer drug resistance: Biological profile, non-coding RNAs, drugs and nanomodulators.Drug Discov. Today2024291110416110.1016/j.drudis.2024.104161 39245345
     [Google Scholar]
  19. HeH. BuckleyM. BrittonB. MuY. WarnerK. KumarS. CoryT.J. Polarized macrophage subsets differentially express the drug efflux transporters MRP1 and BCRP, resulting in altered HIV production.Antivir. Chem. Chemother.2018262040206617745168.10.1177/2040206617745168 29343083
     [Google Scholar]
  20. QinQ. JiH. LiD. ZhangH. ZhangZ. ZhangQ. Tumor-associated macrophages increase COX-2 expression promoting endocrine resistance in breast cancer via the PI3K/Akt/mTOR pathway.Neoplasma202168593894610.4149/neo_2021_201226N1404 34619972
     [Google Scholar]
  21. FuX.T. SongK. ZhouJ. ShiY.H. LiuW.R. ShiG.M. GaoQ. WangX.Y. DingZ.B. FanJ. Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma.Cancer Cell Int.20191917110.1186/s12935‑019‑0771‑8 30962765
     [Google Scholar]
  22. LiY. YinY. ZhangT. WangJ. GuoZ. LiY. ZhaoY. QinR. HeQ. A comprehensive landscape analysis of autophagy in cancer development and drug resistance.Front. Immunol.202415141278110.3389/fimmu.2024.1412781 39253092
     [Google Scholar]
  23. DeligneC. MidwoodK.S. Macrophages and extracellular matrix in breast cancer: Partners in crime or protective allies?Front. Oncol.20211162077310.3389/fonc.2021.620773 33718177
     [Google Scholar]
  24. YuK.X. YuanW.J. WangH.Z. LiY.X. Extracellular matrix stiffness and tumor-associated macrophage polarization: New fields affecting immune exclusion.Cancer Immunol. Immunother.202473611510.1007/s00262‑024‑03675‑9 38693304
     [Google Scholar]
  25. PanchabhaiS. KelemenK. AhmannG. SebastianS. ManteiJ. FonsecaR. Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma.Leukemia201630495195410.1038/leu.2015.191 26202926
     [Google Scholar]
  26. KangS.U. ChoS.Y. JeongH. HanJ. ChaeH.Y. YangH. SungC.O. ChoiY.L. ShinY.K. KwonM.J. Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2–CCR2 signaling.Lab. Invest.2022102437639010.1038/s41374‑021‑00699‑y 34775491
     [Google Scholar]
  27. LiX. ChenL. PengX. ZhanX. Progress of tumor-associated macrophages in the epithelial-mesenchymal transition of tumor.Front. Oncol.20221291141010.3389/fonc.2022.911410 35965509
     [Google Scholar]
  28. KuwadaK. KagawaS. YoshidaR. SakamotoS. ItoA. WatanabeM. IedaT. KurodaS. KikuchiS. TazawaH. FujiwaraT. The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer.J. Exp. Clin. Cancer Res.201837130710.1186/s13046‑018‑0981‑2 30537992
     [Google Scholar]
  29. GazzilloA. PolidoroM.A. SoldaniC. FranceschiniB. LleoA. DonadonM. Relationship between epithelial-to-mesenchymal transition and tumor-associated macrophages in colorectal liver metastases.Int. J. Mol. Sci.202223241619710.3390/ijms232416197 36555840
     [Google Scholar]
  30. AllavenaP. DigificoE. BelgiovineC. Macrophages and cancer stem cells: A malevolent alliance.Mol. Med.202127112110.1186/s10020‑021‑00383‑3 34583655
     [Google Scholar]
  31. RaggiC. MousaH.S. CorrentiM. SicaA. InvernizziP. Cancer stem cells and tumor-associated macrophages: A roadmap for multitargeting strategies.Oncogene201635667168210.1038/onc.2015.132 25961921
     [Google Scholar]
  32. GhandadiM. SahebkarA. Interleukin-6: A critical cytokine in cancer multidrug resistance.Curr. Pharm. Des.201622551852610.2174/1381612822666151124234417 26601970
     [Google Scholar]
  33. WangS. WangJ. ChenZ. LuoJ. GuoW. SunL. LinL. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance.NPJ Precis. Oncol.2024813110.1038/s41698‑024‑00522‑z 38341519
     [Google Scholar]
  34. VirreyJ.J. GuanS. LiW. SchönthalA.H. ChenT.C. HofmanF.M. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells.Am. J. Pathol.2008173257558510.2353/ajpath.2008.071079 18599610
     [Google Scholar]
  35. WangX.L. JiangJ.T. WuC.P. Prognostic significance of tumor-associated macrophage infiltration in gastric cancer: A meta-analysis.Genet. Mol. Res.2016154gmr1504904010.4238/gmr15049040 27966749
     [Google Scholar]
  36. WangX. LiY. PuX. LiuG. QinH. WanW. WangY. ZhuY. YangJ. Macrophage-related therapeutic strategies: Regulation of phenotypic switching and construction of drug delivery systems.Pharmacol. Res.202419910702210.1016/j.phrs.2023.107022 38043691
     [Google Scholar]
  37. KanO. DayD. IqballS. BurkeF. GrimshawM.J. NaylorS. BinleyK. Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer.Int. J. Mol. Med.201127217318010.3892/ijmm.2010.583 21165551
     [Google Scholar]
  38. LiuM-Q. ZhangJ-W. ZhuJ-W. Roles of tumor-associated macrophages in tumor environment and strategies for targeting therapy. Pharma.Fronts202354e254e27310.1055/s‑0043‑1777704
     [Google Scholar]
  39. TumehP.C. HarviewC.L. YearleyJ.H. ShintakuI.P. TaylorE.J.M. RobertL. ChmielowskiB. SpasicM. HenryG. CiobanuV. WestA.N. CarmonaM. KivorkC. SejaE. CherryG. GutierrezA.J. GroganT.R. MateusC. TomasicG. GlaspyJ.A. EmersonR.O. RobinsH. PierceR.H. ElashoffD.A. RobertC. RibasA. PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature2014515752856857110.1038/nature13954 25428505
     [Google Scholar]
  40. SianV. SoutoJ.A. AlvarezR. NebbiosoA. de LeraA.R. AltucciL. Chapter 17 -Inhibitors of Jumonji-C domain-containing histone demethylases.Epigenetic Cancer Therapy.2nd edCambridge, USAcademic Press202340745710.1016/B978‑0‑323‑91367‑6.00025‑8
     [Google Scholar]
  41. ZhuC. KrosJ.M. ChengC. MustafaD. The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.Neuro-oncol.201719111435144610.1093/neuonc/nox081 28575312
     [Google Scholar]
  42. NiuM. ValdesS. NaguibY.W. HurstingS.D. CuiZ. Tumor-associated macrophage-mediated targeted therapy of triple-negative breast cancer.Mol. Pharm.20161361833184210.1021/acs.molpharmaceut.5b00987 27074028
     [Google Scholar]
  43. AhegetH. MaziniL. MartinF. BelqatB. MarchalJ.A. BenabdellahK. Exosomes: Their role in pathogenesis, diagnosis and treatment of diseases.Cancers (Basel)20201318410.3390/cancers13010084 33396739
     [Google Scholar]
  44. DallavalasaS. BeerakaN.M. BasavarajuC.G. TulimilliS.V. SadhuS.P. RajeshK. AlievG. MadhunapantulaS.V. The role of tumor associated macrophages (TAMs) in cancer progression, chemoresistance, angiogenesis and metastasis-current status.Curr. Med. Chem.202128398203823610.2174/1875533XMTE20ODIe4 34303328
     [Google Scholar]
  45. IshikawaE. MiyazakiT. TakanoS. AkutsuH. Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy.Brain Tumor Pathol.202138314915510.1007/s10014‑021‑00402‑5 33977360
     [Google Scholar]
  46. QianS. WeiZ. YangW. HuangJ. YangY. WangJ. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy.Front. Oncol.20221298536310.3389/fonc.2022.985363 36313628
     [Google Scholar]
  47. DaiE. ZhuZ. WahedS. QuZ. StorkusW.J. GuoZ.S. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.Mol. Cancer202120117110.1186/s12943‑021‑01464‑x 34930302
     [Google Scholar]
  48. ChristofiT. BaritakiS. FalzoneL. LibraM. ZaravinosA. Current perspectives in cancer immunotherapy.Cancers (Basel)20191110147210.3390/cancers11101472 31575023
     [Google Scholar]
  49. LiuJ. GengX. HouJ. WuG. New insights into M1/M2 macrophages: Key modulators in cancer progression.Cancer Cell Int.202121138910.1186/s12935‑021‑02089‑2 34289846
     [Google Scholar]
  50. BaiH. FengL. SchmidF. Macrophage-based cancer immunotherapy: Challenges and opportunities.Exp. Cell Res.2024442111419810.1016/j.yexcr.2024.114198 39103071
     [Google Scholar]
  51. AhluwaliaP. AhluwaliaM. MondalA.K. SahajpalN.S. KotaV. RojianiM.V. KolheR. Natural killer cells and dendritic cells: Expanding clinical relevance in the non-small cell lung cancer (NSCLC) tumor microenvironment.Cancers (Basel)20211316403710.3390/cancers13164037 34439191
     [Google Scholar]
  52. PetersonE.E. BarryK.C. The natural killer–dendritic cell immune axis in anti-cancer immunity and immunotherapy.Front. Immunol.20211162125410.3389/fimmu.2020.621254 33613552
     [Google Scholar]
  53. FiedlerE.C. HemannM.T. Aiding and abetting: How the tumor microenvironment protects cancer from chemotherapy.Annu. Rev. Cancer Biol.20193140942810.1146/annurev‑cancerbio‑030518‑055524
     [Google Scholar]
  54. KhalafK. HanaD. ChouJ.T.T. SinghC. MackiewiczA. KaczmarekM. Aspects of the tumor microenvironment involved in immune resistance and drug resistance.Front. Immunol.20211265636410.3389/fimmu.2021.656364 34122412
     [Google Scholar]
  55. JingX. YangF. ShaoC. WeiK. XieM. ShenH. ShuY. Role of hypoxia in cancer therapy by regulating the tumor microenvironment.Mol. Cancer201918115710.1186/s12943‑019‑1089‑9 31711497
     [Google Scholar]
  56. Emami NejadA. NajafgholianS. RostamiA. SistaniA. ShojaeifarS. EsparvarinhaM. NedaeiniaR. Haghjooy JavanmardS. TaherianM. AhmadlouM. SalehiR. SadeghiB. ManianM. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: A novel approach to developing treatment.Cancer Cell Int.20212116210.1186/s12935‑020‑01719‑5 33472628
     [Google Scholar]
  57. HuangK. ZhangX. HaoY. FengR. WangH. ShuZ. LiA. DuM. Hypoxia tumor microenvironment activates GLI2 through HIF-1α and TGF-β2 to promote chemotherapy resistance of colorectal cancer.Comput. Math. Methods Med.202220221710.1155/2022/2032895 35186110
     [Google Scholar]
  58. ChenG. WuK. LiH. XiaD. HeT. Role of hypoxia in the tumor microenvironment and targeted therapy.Front. Oncol.20221296163710.3389/fonc.2022.961637 36212414
     [Google Scholar]
  59. YuanZ. LiY. ZhangS. WangX. DouH. YuX. ZhangZ. YangS. XiaoM. Extracellular matrix remodeling in tumor progression and immune escape: From mechanisms to treatments.Mol. Cancer20232214810.1186/s12943‑023‑01744‑8 36906534
     [Google Scholar]
  60. ShermanM.H. BeattyG.L. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance.Annu. Rev. Pathol.20231812314810.1146/annurev‑pathmechdis‑031621‑024600 36130070
     [Google Scholar]
  61. EstephanL.E. KumarG. StewartM. BanoubR. LinnenbachA. HarshyneL.A. Martinez-OutschoornU.E. MahoneyM.G. CurryJ.M. JohnsonJ. SouthA.P. LuginbuhlA.J. Altered extracellular matrix correlates with an immunosuppressive tumor microenvironment and disease progression in younger adults with oral cavity squamous cell carcinoma.Front. Oncol.202414141221210.3389/fonc.2024.1412212 38957320
     [Google Scholar]
  62. GaoY. ZhouH. LiuG. WuJ. YuanY. ShangA. Tumor microenvironment: Lactic acid promotes tumor development.J. Immunol. Res.202220221810.1155/2022/3119375 35733921
     [Google Scholar]
  63. KimI. ChoiS. YooS. LeeM. KimI.S. Cancer-associated fibroblasts in the hypoxic tumor microenvironment.Cancers (Basel)20221414332110.3390/cancers14143321 35884382
     [Google Scholar]
  64. SarkarM. NguyenT. GundreE. OgunlusiO. El-SobkyM. GiriB. SarkarT.R. Cancer-associated fibroblasts: The chief architect in the tumor microenvironment.Front. Cell Dev. Biol.202311108906810.3389/fcell.2023.1089068 36793444
     [Google Scholar]
  65. SobierajskaK. CiszewskiW.M. Sacewicz-HofmanI. NiewiarowskaJ. Endothelial cells in the tumor microenvironment.Adv. Exp. Med. Biol.20201234718610.1007/978‑3‑030‑37184‑5_6
     [Google Scholar]
  66. López de AndrésJ. Griñán-LisónC. JiménezG. MarchalJ.A. Cancer stem cell secretome in the tumor microenvironment: A key point for an effective personalized cancer treatment.J. Hematol. Oncol.202013113610.1186/s13045‑020‑00966‑3 33059744
     [Google Scholar]
  67. GuoQ. ZhouY. XieT. YuanY. LiH. ShiW. ZhengL. LiX. ZhangW. Tumor microenvironment of cancer stem cells: Perspectives on cancer stem cell targeting.Genes Dis.202411310104310.1016/j.gendis.2023.05.024 38292177
     [Google Scholar]
  68. WuB. ShiX. JiangM. LiuH. Cross-talk between cancer stem cells and immune cells: Potential therapeutic targets in the tumor immune microenvironment.Mol. Cancer20232213810.1186/s12943‑023‑01748‑4 36810098
     [Google Scholar]
  69. ZhuS. LiS. YiM. LiN. WuK. Roles of microvesicles in tumor progression and clinical applications.Int. J. Nanomedicine2021167071709010.2147/IJN.S325448 34703228
     [Google Scholar]
  70. RatajczakM.Z. RatajczakJ. Extracellular microvesicles/exo-somes: Discovery, disbelief, acceptance, and the future?Leukemia202034123126313510.1038/s41375‑020‑01041‑z 32929129
     [Google Scholar]
  71. ZelliV. CompagnoniC. CapelliR. CorrenteA. Di Vito NolfiM. ZazzeroniF. AlesseE. TessitoreA. Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: Focus on hepatocellular carcinoma.Front. Oncol.20221294005610.3389/fonc.2022.940056 35912267
     [Google Scholar]
  72. JenaB.C. MandalM. The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction.Biochim. Biophys. Acta Rev. Cancer20211875118848810.1016/j.bbcan.2020.188488 33271308
     [Google Scholar]
  73. TaebS. AshrafizadehM. ZarrabiA. RezapoorS. MusaA.E. FarhoodB. NajafiM. Role of tumor microenvironment in cancer stem cells resistance to radiotherapy.Curr. Cancer Drug Targets2022221183010.2174/1568009622666211224154952 34951575
     [Google Scholar]
  74. GarajováI. BalsanoR. WangH. LeonardiF. GiovannettiE. DengD. PetersG.J. The role of the microbiome in drug resistance in gastrointestinal cancers.Expert Rev. Anticancer Ther.202121216517610.1080/14737140.2021.1844007 33115280
     [Google Scholar]
  75. ShuiL. YangX. LiJ. YiC. SunQ. ZhuH. Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy.Front. Immunol.202010298910.3389/fimmu.2019.02989 32010123
     [Google Scholar]
  76. PandeyK. UmarS. Microbiome in drug resistance to colon cancer.Curr. Opin. Physiol.20212310047210.1016/j.cophys.2021.100472 34514218
     [Google Scholar]
  77. ChauC.H. SteegP.S. FiggW.D. Antibody–drug conjugates for cancer.Lancet20193941020079380410.1016/S0140‑6736(19)31774‑X 31478503
     [Google Scholar]
  78. WellsK. LiuT. ZhuL. YangL. Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy.Nanoscale20241638176991772210.1039/D4NR01780C 39257225
     [Google Scholar]
  79. PalazzoloS. BaydaS. HadlaM. CaligiuriI. CoronaG. ToffoliG. RizzolioF. The clinical translation of organic nanomaterials for cancer therapy: A focus on polymeric nanoparticles, micelles, liposomes and exosomes.Curr. Med. Chem.201825344224426810.2174/0929867324666170830113755 28875844
     [Google Scholar]
  80. BramelE.R. SiaD. Novel insights into molecular and immune subtypes of biliary tract cancers.Adv. Cancer Res.202215616719910.1016/bs.acr.2022.01.008 35961699
     [Google Scholar]
  81. XuY. XiongJ. SunX. GaoH. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy.Acta Pharm. Sin. B202212124327434710.1016/j.apsb.2022.11.001 36561994
     [Google Scholar]
  82. ChikumaS. KanamoriM. Mise-OmataS. YoshimuraA. Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy.Cancer Sci.2017108457458010.1111/cas.13194 28188673
     [Google Scholar]
  83. LawlerS.E. SperanzaM.C. ChoC.F. ChioccaE.A. Oncolytic viruses in cancer treatment: A review.JAMA Oncol.20173684184910.1001/jamaoncol.2016.2064 27441411
     [Google Scholar]
  84. SternerR.C. SternerR.M. CAR-T cell therapy: Current limitations and potential strategies.Blood Cancer J.20211146910.1038/s41408‑021‑00459‑7 33824268
     [Google Scholar]
  85. WolfN.K. KissiovD.U. RauletD.H. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy.Nat. Rev. Immunol.20232329010510.1038/s41577‑022‑00732‑1 35637393
     [Google Scholar]
  86. LiuY. LiangJ. ZhangY. GuoQ. Drug resistance and tumor immune microenvironment: An overview of current understandings (Review).Int. J. Oncol.20246549610.3892/ijo.2024.5684 39219258
     [Google Scholar]
  87. ColeyH.M. Overcoming multidrug resistance in cancer: Clinical studies of p-glycoprotein inhibitors.Meth. Mol. Biol.201059634135810.1007/978‑1‑60761‑416‑6_15 19949931
     [Google Scholar]
  88. QinY. AshrafizadehM. MongiardiniV. GrimaldiB. CreaF. RietdorfK. GyőrffyB. KlionskyD.J. RenJ. ZhangW. ZhangX. Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence.Cancer Lett.202357021630710.1016/j.canlet.2023.216307 37451426
     [Google Scholar]
  89. GrégoireH. RoncaliL. RousseauA. ChérelM. DelnesteY. JeanninP. HindréF. GarcionE. Targeting tumor associated macrophages to overcome conventional treatment resistance in glioblastoma.Front. Pharmacol.20201136810.3389/fphar.2020.00368 32322199
     [Google Scholar]
  90. MantovaniA. SozzaniS. LocatiM. AllavenaP. SicaA. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.Trends Immunol.2002231154955510.1016/S1471‑4906(02)02302‑5 12401408
     [Google Scholar]
  91. ZhangJ. HuC. ZhangR. XuJ. ZhangY. YuanL. ZhangS. PanS. CaoM. QinJ. ChengX. XuZ. The role of macrophages in gastric cancer.Front. Immunol.202314128217610.3389/fimmu.2023.1282176 38143746
     [Google Scholar]
  92. PouraliG. ZafariN. VelayatiM. MehrabadiS. MaftoohM. HassanianS.M. MobarhanG.M. FernsG.A. AvanA. KhazaeiM. Therapeutic potential of targeting transforming growth factor-beta (TGF-β) and programmed death-ligand 1 (PD-L1) in pancreatic cancer.Curr. Drug Targets202324171335134510.2174/0113894501264450231129042256 38053355
     [Google Scholar]
  93. PatilV.M. Role of CSF1R inhibitor pexidartinib for the treatment of cancer.Russ. J. Bioorganic Chem.202248S1S1S810.1134/S1068162023010223
     [Google Scholar]
  94. DowlatiA. HarveyR.D. CarvajalR.D. HamidO. KlempnerS.J. KauhJ.S.W. PetersonD.A. YuD. ChapmanS.C. SzpurkaA.M. CarlsenM. QuinlanT. WesolowskiR. LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: Phase 1 dose-escalation trial.Invest. New Drugs20213941057107110.1007/s10637‑021‑01084‑8 33624233
     [Google Scholar]
  95. PathriaP. LouisT.L. VarnerJ.A. Targeting tumor-associated macrophages in cancer.Trends Immunol.201940431032710.1016/j.it.2019.02.003 30890304
     [Google Scholar]
  96. NowakM. KlinkM. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer.Cells202095129910.3390/cells9051299 32456078
     [Google Scholar]
  97. SugawaraT. FrancoR.S. ShermanS. KirschM.J. ColbornK. IshidaJ. GrandiS. Al-MusawiM.H. GleisnerA. SchulickR.D. Del ChiaroM. Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy.JAMA Oncol.20239331632310.1001/jamaoncol.2022.5808 36480190
     [Google Scholar]
  98. ChenY. JinH. SongY. HuangT. CaoJ. TangQ. ZouZ. Targeting tumor‐associated macrophages: A potential treatment for solid tumors.J. Cell. Physiol.202123653445346510.1002/jcp.30139 33200401
     [Google Scholar]
  99. FosterC.C. FlemingG.F. KarrisonT.G. LiaoC.Y. DesaiA.V. MoroneyJ.W. RatainM.J. NandaR. PoliteB.N. HahnO.M. O’DonnellP.H. VokesE.E. KindlerH.L. HseuR. JanischL.A. DaiJ. HoffmanM.D. WeichselbaumR.R. PitrodaS.P. ChmuraS.J. LukeJ.J. Phase I study of stereotactic body radiotherapy plus nivolumab and urelumab or cabiralizumab in advanced solid tumors.Clin. Cancer Res.202127205510551810.1158/1078‑0432.CCR‑21‑0810 34168049
     [Google Scholar]
  100. PohA.R. ErnstM. Tumor-associated macrophages in pancreatic ductal adenocarcinoma: Therapeutic opportunities and clinical challenges.Cancers (Basel)20211312286010.3390/cancers13122860 34201127
     [Google Scholar]
  101. PollardJ.W. Trophic macrophages in development and disease.Nat. Rev. Immunol.20099425927010.1038/nri2528 19282852
     [Google Scholar]
  102. BeheshtizadehN. AmiriZ. TabatabaeiS.Z. SerajiA.A. GharibshahianM. NadiA. SaeinasabM. SefatF. Kolahi AzarH. Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: From cancer therapy to regenerative medicine approaches.J. Transl. Med.202422152010.1186/s12967‑024‑05347‑9 38816723
     [Google Scholar]
  103. HoW.J. JaffeeE.M. Macrophage-targeting by CSF1/1R blockade in pancreatic cancers.Cancer Res.202181246071607310.1158/0008‑5472.CAN‑21‑3603 34911778
     [Google Scholar]
  104. De PalmaM. LewisC.E. Macrophage regulation of tumor responses to anticancer therapies.Cancer Cell201323327728610.1016/j.ccr.2013.02.013 23518347
     [Google Scholar]
  105. GinhouxF. GuilliamsM. Tissue-resident macrophage ontogeny and homeostasis.Immunity201644343944910.1016/j.immuni.2016.02.024 26982352
     [Google Scholar]
  106. XuY. WangX. LiuL. WangJ. WuJ. SunC. Role of macrophages in tumor progression and therapy (Review).Int. J. Oncol.20226055710.3892/ijo.2022.5347 35362544
     [Google Scholar]
  107. RuffellB. AffaraN.I. CoussensL.M. Differential macrophage programming in the tumor microenvironment.Trends Immunol.201233311912610.1016/j.it.2011.12.001 22277903
     [Google Scholar]
  108. WangS. YangY. MaP. HuangH. TangQ. MiaoH. FangY. JiangN. LiY. ZhuQ. TaoW. ZhaY. LiN. Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials.Mol. Ther. Oncolytics20222479981310.1016/j.omto.2022.02.019 35317518
     [Google Scholar]
  109. FalleniM. SaviF. TosiD. AgapeE. CerriA. MoneghiniL. BulfamanteG.P. M1 and M2 macrophages’ clinicopathological significance in cutaneous melanoma.Melanoma Res.201727320021010.1097/CMR.0000000000000352 28272106
     [Google Scholar]
  110. TruxovaI. CibulaD. SpisekR. FucikovaJ. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.J. Immunother. Cancer2023112e00596810.1136/jitc‑2022‑005968 36822672
     [Google Scholar]
  111. ZhangW. ZhuX.D. SunH.C. XiongY.Q. ZhuangP.Y. XuH.X. KongL.Q. WangL. WuW.Z. TangZ.Y. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.Clin. Cancer Res.201016133420343010.1158/1078‑0432.CCR‑09‑2904 20570927
     [Google Scholar]
  112. YadavK. PradhanM. SinghD. SinghM.R. Macrophage-associated disorders: Pathophysiology, treatment challenges, and possible solutions.Macrophage Targeted Delivery Systems.ChamSpringer2022659910.1007/978‑3‑030‑84164‑5_4
     [Google Scholar]
  113. DeNardoD.G. BarretoJ.B. AndreuP. VasquezL. TawfikD. KolhatkarN. CoussensL.M. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.Cancer Cell20091629110210.1016/j.ccr.2009.06.018 19647220
     [Google Scholar]
  114. WeissS.A. DjureinovicD. JesselS. KrykbaevaI. ZhangL. JilaveanuL. RalabateA. JohnsonB. LevitN.S. AndersonG. ZeltermanD. WeiW. MahajanA. TrifanO. BosenbergM. KaechS.M. PerryC.J. DamskyW. GettingerS. SznolM. HurwitzM. KlugerH.M. A phase I study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non–small cell lung cancer resistant to anti-PD-1/PD-L1.Clin. Cancer Res.202127174757476710.1158/1078‑0432.CCR‑21‑0903 34140403
     [Google Scholar]
  115. WainbergZ.A. EisenbergP.D. SachdevJ.C. WeiseA.M. KaufmanD.R. HutchinsonM. Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors J.Clini. Oncol.201634446510.1200/jco.2016.34.4_suppl.tps465
     [Google Scholar]
  116. LiC. XuX. WeiS. JiangP. XueL. WangJ. Tumor-associated macrophages: Potential therapeutic strategies and future prospects in cancer.J. Immunother. Cancer202191e00134110.1136/jitc‑2020‑001341 33504575
     [Google Scholar]
  117. PohA.R. ErnstM. Targeting macrophages in cancer: From bench to bedside.Front. Oncol.201884910.3389/fonc.2018.00049 29594035
     [Google Scholar]
  118. SteevesJ.D. Bench to bedside.Prog. Brain Res.201521822723910.1016/bs.pbr.2014.12.008 25890140
     [Google Scholar]
  119. PaganiniC. PalmieroC.U. PocsfalviG. TouzetN. BongiovanniA. ArosioP. Scalable production and isolation of extracellular vesicles: Available sources and lessons from current industrial bioprocesses.Biotechnol. J.20191410180052810.1002/biot.201800528 31140717
     [Google Scholar]
  120. MantovaniA. AllavenaP. MarchesiF. GarlandaC. Macrophages as tools and targets in cancer therapy.Nat. Rev. Drug Discov.2022211179982010.1038/s41573‑022‑00520‑5 35974096
     [Google Scholar]
  121. SluijterM. van der SluisT.C. van der VeldenP.A. VersluisM. WestB.L. van der BurgS.H. van HallT. Inhibition of CSF-1R supports T-cell mediated melanoma therapy.PLoS One201498e10423010.1371/journal.pone.0104230 25110953
     [Google Scholar]
  122. HuangY. WangZ. GongJ. ZhuD. ChenW. LiF. LiangX.J. LiuX. Macrophages as potential targets in gene therapy for cancer treatment.Explor. Target. Antitumor Ther.2023418910110.37349/etat.2023.00124 36937317
     [Google Scholar]
  123. QiuX. ZhaoT. LuoR. QiuR. LiZ. Tumor-associated macrophages: Key players in triple-negative breast cancer.Front. Oncol.20221277261510.3389/fonc.2022.772615 35237507
     [Google Scholar]
  124. KhanS.U. KhanM.U. Azhar Ud DinM. KhanI.M. KhanM.I. BungauS. HassanS.S. Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy.Front. Immunol.202314116648710.3389/fimmu.2023.1166487 37138860
     [Google Scholar]
  125. JianC.Z. LinL. HsuC.L. ChenY.H. HsuC. TanC.T. OuD.L. A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies.Drug Discov. Today202429310389310.1016/j.drudis.2024.103893 38272173
     [Google Scholar]
  126. ChakrabortyS. YeJ. WangH. SunM. ZhangY. SangX. ZhuangZ. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.Front. Immunol.202314122783310.3389/fimmu.2023.1227833 37936697
     [Google Scholar]
  127. ZengQ. JewellC.M. Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy.Curr. Opin. Biotechnol.20196013814510.1016/j.copbio.2019.01.010 30831487
     [Google Scholar]
  128. GlavianoA. FooA.S.C. LamH.Y. YapK.C.H. JacotW. JonesR.H. EngH. NairM.G. MakvandiP. GeoergerB. KulkeM.H. BairdR.D. PrabhuJ.S. CarboneD. PecoraroC. TehD.B.L. SethiG. CavalieriV. LinK.H. Javidi-SharifiN.R. ToskaE. DavidsM.S. BrownJ.R. DianaP. StebbingJ. FrumanD.A. KumarA.P. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.Mol. Cancer202322113810.1186/s12943‑023‑01827‑6 37596643
     [Google Scholar]
  129. LintonM.F. MoslehiJ.J. BabaevV.R. Akt signaling in macrophage polarization, survival, and atherosclerosis.Int. J. Mol. Sci.20192011270310.3390/ijms20112703 31159424
     [Google Scholar]
  130. XiaT. ZhangM. LeiW. YangR. FuS. FanZ. YangY. ZhangT. Advances in the role of STAT3 in macrophage polarization.Front. Immunol.202314116071910.3389/fimmu.2023.1160719 37081874
     [Google Scholar]
  131. De PalmaM. BiziatoD. PetrovaT.V. Microenvironmental regulation of tumour angiogenesis.Nat. Rev. Cancer201717845747410.1038/nrc.2017.51 28706266
     [Google Scholar]
  132. HeW. KapateN. ShieldsC.W.IV MitragotriS. Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases.Adv. Drug Deliv. Rev.2020165-166154010.1016/j.addr.2019.12.001 31816357
     [Google Scholar]
  133. AndersonN.R. MinutoloN.G. GillS. KlichinskyM. Macrophage-based approaches for cancer immunotherapy.Cancer Res.20218151201120810.1158/0008‑5472.CAN‑20‑2990 33203697
     [Google Scholar]
  134. LiM. YangY. XiongL. JiangP. WangJ. LiC. Metabolism, metabolites, and macrophages in cancer.J. Hematol. Oncol.20231618010.1186/s13045‑023‑01478‑6 37491279
     [Google Scholar]
  135. WangY. YuG. LiuY. XieL. GeJ. ZhaoG. LinJ. Hypoxia-induced PTTG3P contributes to colorectal cancer glycolysis and M2 phenotype of macrophage.Biosci. Rep.2021417BSR2021076410.1042/BSR20210764 34132347
     [Google Scholar]
  136. WangH. WangL. PanH. WangY. ShiM. YuH. WangC. PanX. ChenZ. Exosomes derived from macrophages enhance aerobic glycolysis and chemoresistance in lung cancer by stabilizing c-Myc via the inhibition of NEDD4L.Front. Cell Dev. Biol.2021862060310.3389/fcell.2020.620603 33748098
     [Google Scholar]
  137. MarcucciF. RumioC. Glycolysis-induced drug resistance in tumors—A response to danger signals?Neoplasia202123223424510.1016/j.neo.2020.12.009 33418276
     [Google Scholar]
  138. LiuH. LvH. DuanX. DuY. TangY. XuW. Advancements in macrophage-targeted drug delivery for effective disease management.Int. J. Nanomedicine2023186915694010.2147/IJN.S430877 38026516
     [Google Scholar]
  139. WróblewskaA. SzczygiełA. Szermer-OlearnikB. Pajtasz-PiaseckaE. Macrophages as promising carriers for nanoparticle delivery in anticancer therapy.Int. J. Nanomedicine2023184521453910.2147/IJN.S421173 37576466
     [Google Scholar]
  140. ZhangY. CaiK. LiC. GuoQ. ChenQ. HeX. LiuL. ZhangY. LuY. ChenX. SunT. HuangY. ChengJ. JiangC. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy.Nano Lett.20181831908191510.1021/acs.nanolett.7b05263 29473753
     [Google Scholar]
  141. FengL. DongZ. TaoD. ZhangY. LiuZ. The acidic tumor microenvironment: A target for smart cancer nano-theranostics.Natl. Sci. Rev.20185226928610.1093/nsr/nwx062
     [Google Scholar]
  142. HosonumaM. YoshimuraK. Association between pH regulation of the tumor microenvironment and immunological state.Front. Oncol.202313117556310.3389/fonc.2023.1175563 37492477
     [Google Scholar]
  143. RuffellB. CoussensL.M. Macrophages and therapeutic resistance in cancer.Cancer Cell201527446247210.1016/j.ccell.2015.02.015 25858805
     [Google Scholar]
  144. DuanZ. LuoY. Targeting macrophages in cancer immunotherapy.Signal Transduct. Target. Ther.20216112710.1038/s41392‑021‑00506‑6 33767177
     [Google Scholar]
  145. XuM. LiS. Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment.Cancer Lett.202357421639710.1016/j.canlet.2023.216397 37730105
     [Google Scholar]
  146. BelgiovineC. DigificoE. AnfrayC. UmmarinoA. Torres AndónF. Targeting tumor-associated macrophages in anti-cancer therapies: Convincing the traitors to do the right thing.J. Clin. Med.2020910322610.3390/jcm9103226 33050070
     [Google Scholar]
  147. GuoQ. QianZ.M. Macrophage based drug delivery: Key challenges and strategies.Bioact. Mater.202438557210.1016/j.bioactmat.2024.04.004 38699242
     [Google Scholar]
  148. GabrilovichD.I. Combination of chemotherapy and immunotherapy for cancer: A paradigm revisited.Lancet Oncol.2007812310.1016/S1470‑2045(06)70985‑8 17196504
     [Google Scholar]
  149. LiJ. WangQ. XiaG. AdilijiangN. LiY. HouZ. FanZ. LiJ. Recent advances in targeted drug delivery strategy for enhancing oncotherapy.Pharmaceutics2023159223310.3390/pharmaceutics15092233 37765202
     [Google Scholar]
  150. SanmamedM.F. ChenL. A paradigm shift in cancer immunotherapy: From enhancement to normalization.Cell2018175231332610.1016/j.cell.2018.09.035 30290139
     [Google Scholar]
  151. TsaoL.C. ForceJ. HartmanZ.C. Mechanisms of therapeutic antitumor monoclonal antibodies.Cancer Res.202181184641465110.1158/0008‑5472.CAN‑21‑1109 34145037
     [Google Scholar]
  152. MalmbergR. ZietseM. DumoulinD.W. HendrikxJ.J.M.A. AertsJ.G.J.V. van der VeldtA.A.M. KochB.C.P. SleijferS. van LeeuwenR.W.F. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: A special focus on nivolumab and pembrolizumab.Lancet Oncol.20222312e552e56110.1016/S1470‑2045(22)00554‑X 36455584
     [Google Scholar]
  153. Dalle VedoveE. CostabileG. MerkelO.M. Mannose and mannose‐6‐phosphate receptor–targeted drug delivery systems and their application in cancer therapy.Adv. Healthc. Mater.2018714170139810.1002/adhm.201701398 29719138
     [Google Scholar]
  154. ThomasT.P. GoonewardenaS.N. MajorosI.J. KotlyarA. CaoZ. LeroueilP.R. BakerJ.R.Jr Folate‐targeted nanoparticles show efficacy in the treatment of inflammatory arthritis.Arthritis Rheum.20116392671268010.1002/art.30459 21618461
     [Google Scholar]
  155. Gonzalez-ValdiviesoJ. VallejoR. Rodriguez-RojoS. SantosM. SchneiderJ. AriasF.J. GirottiA. CD44-targeted nanoparticles for co-delivery of docetaxel and an Akt inhibitor against colorectal cancer.Biomater. Adv.202315421359510.1016/j.bioadv.2023.213595 37639856
     [Google Scholar]
  156. SuksiriworapongJ. PongprasertN. BunsupaS. TarescoV. CrucittiV.C. JanuraiT. PhruttiwanichakunP. SakchaisriK. WongrakpanichA. CD44-targeted lipid polymer hybrid nanoparticles enhance anti-breast cancer effect of Cordyceps militaris extracts.Pharmaceutics2023156177110.3390/pharmaceutics15061771 37376218
     [Google Scholar]
  157. YangP. ZhangL. WangT. LiuQ. WangJ. WangY. TuZ. LinF. Doxorubicin and edelfosine combo-loaded lipid–polymer hybrid nanoparticles for synergistic anticancer effect against drug-resistant osteosarcoma.OncoTargets Ther.2020138055806710.2147/OTT.S259428 32884291
     [Google Scholar]
  158. CendrowiczE. SasZ. BremerE. RygielT.P. The role of macrophages in cancer development and therapy.Cancers2021138194610.3390/cancers13081946 33919517
     [Google Scholar]
  159. ZhangW. Taheri-LedariR. GanjaliF. MirmohammadiS.S. QaziF.S. SaeidiradM. KashtiArayA. Zarei-ShokatS. TianY. MalekiA. Effects of morphology and size of nanoscale drug carriers on cellular uptake and internalization process: A review.RSC Advances20221318011410.1039/D2RA06888E 36605676
     [Google Scholar]
  160. GhazalH. WaqarA. YaseenF. ShahidM. SultanaM. TariqM. Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment.Next Materials2024210012810.1016/j.nxmate.2024.100128
     [Google Scholar]
  161. MusyanovychA. DausendJ. DassM. WaltherP. MailänderV. LandfesterK. Criteria impacting the cellular uptake of nanoparticles: A study emphasizing polymer type and surfactant effects.Acta Biomater.20117124160416810.1016/j.actbio.2011.07.033 21855659
     [Google Scholar]
  162. AfzalO. AltamimiA.S.A. NadeemM.S. AlzareaS.I. AlmalkiW.H. TariqA. Nanoparticles in drug delivery: From history to therapeutic applications.Nanomaterials20221224449410.3390/nano12244494 36558344
     [Google Scholar]
  163. KottaS. AldawsariH.M. Badr-EldinS.M. NairA.B. Progress in polymeric micelles for drug delivery applications.Pharmaceutics2022148163610.3390/pharmaceutics14081636 36015262
     [Google Scholar]
  164. KyriakidesT.R. RajA. TsengT.H. XiaoH. NguyenR. MohammedF.S. HalderS. XuM. WuM.J. BaoS. SheuW.C. Biocompatibility of nanomaterials and their immunological properties.Biomed. Mater.202116404200510.1088/1748‑605X/abe5fa 33578402
     [Google Scholar]
  165. MaedaH. SawaT. KonnoT. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.J. Control. Release2001741-3476110.1016/S0168‑3659(01)00309‑1 11489482
     [Google Scholar]
  166. CabralH. MatsumotoY. MizunoK. ChenQ. MurakamiM. KimuraM. TeradaY. KanoM.R. MiyazonoK. UesakaM. NishiyamaN. KataokaK. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size.Nat. Nanotechnol.201161281582310.1038/nnano.2011.166 22020122
     [Google Scholar]
  167. PerraultS.D. WalkeyC. JenningsT. FischerH.C. ChanW.C.W. Mediating tumor targeting efficiency of nanoparticles through design.Nano Lett.2009951909191510.1021/nl900031y 19344179
     [Google Scholar]
  168. ParmarK. PatelJ. PathakY. Factors affecting the clearance and biodistribution of polymeric nanoparticles.Pharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems.ChamSpringer202226127210.1007/978‑3‑030‑83395‑4_14
     [Google Scholar]
  169. OussorenC. ZuidemaJ. CrommelinD.J.A. StormG. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.Biochim. Biophys. Acta Biomembr.19971328226127210.1016/S0005‑2736(97)00122‑3
     [Google Scholar]
  170. GengY. DalhaimerP. CaiS. TsaiR. TewariM. MinkoT. DischerD.E. Shape effects of filaments versus spherical particles in flow and drug delivery.Nat. Nanotechnol.20072424925510.1038/nnano.2007.70 18654271
     [Google Scholar]
  171. ZhangJ. ZhouX. HaoH. Macrophage phenotype-switching in cancer.Eur. J. Pharmacol.202293117522910.1016/j.ejphar.2022.175229 36002039
     [Google Scholar]
  172. WangH. YangL. WangD. ZhangQ. ZhangL. Pro-tumor activities of macrophages in the progression of melanoma.Hum. Vaccin. Immunother.20171371556156210.1080/21645515.2017.1312043 28441072
     [Google Scholar]
  173. DingY. CaoQ. YangW. XuJ. XiaoP. Macrophage: Hidden criminal in therapy resistance.J. Innate Immun.202416118820210.1159/000538212 38442696
     [Google Scholar]
  174. WangP. ZhangY. LeiH. YuJ. ZhouQ. ShiX. ZhuY. ZhangD. ZhangP. WangK. DongK. XingJ. DongY. Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis.Carbohydr. Polym.202331612101810.1016/j.carbpol.2023.121018 37321721
     [Google Scholar]
  175. SubhanM.A. YalamartyS.S.K. FilipczakN. ParveenF. TorchilinV.P. Recent advances in tumor targeting via EPR effect for cancer treatment.J. Pers. Med.202111657110.3390/jpm11060571 34207137
     [Google Scholar]
  176. EmensL.A. RomeroP.J. AndersonA.C. BrunoT.C. CapitiniC.M. CollyarD. GulleyJ.L. HwuP. PoseyA.D.Jr SilkA.W. WargoJ.A. Challenges and opportunities in cancer immunotherapy: A Society for Immunotherapy of Cancer (SITC) strategic vision.J. Immunother. Cancer2024126e00906310.1136/jitc‑2024‑009063 38901879
     [Google Scholar]
  177. YarchoanM. AlbackerL.A. HopkinsA.C. MontesionM. MurugesanK. VithayathilT.T. ZaidiN. AzadN.S. LaheruD.A. FramptonG.M. JaffeeE.M. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.JCI Insight201946e12690810.1172/jci.insight.126908 30895946
     [Google Scholar]
  178. HorganR.P. KennyL.C. ‘Omic’ technologies: Genomics, transcriptomics, proteomics and metabolomics.Obstet. Gynaecol.201113318919510.1576/toag.13.3.189.27672
     [Google Scholar]
  179. MenyhártO. GyőrffyB. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis.Comput. Struct. Biotechnol. J.20211994996010.1016/j.csbj.2021.01.009 33613862
     [Google Scholar]
  180. OelkrugC. RamageJ.M. Enhancement of T cell recruitment and infiltration into tumours.Clin. Exp. Immunol.201417811810.1111/cei.12382 24828133
     [Google Scholar]
  181. HouotR. SchultzL.M. MarabelleA. KohrtH. T-cell–based immunotherapy: Adoptive cell transfer and checkpoint inhibition.Cancer Immunol. Res.20153101115112210.1158/2326‑6066.CIR‑15‑0190 26438444
     [Google Scholar]
  182. Dianat-MoghadamH. NedaeiniaR. KeshavarzM. AziziM. KazemiM. SalehiR. Immunotherapies targeting tumor vasculature: Challenges and opportunities.Front. Immunol.202314122636010.3389/fimmu.2023.1226360 37727791
     [Google Scholar]
  183. WangH. YungM.M.H. NganH.Y.S. ChanK.K.L. ChanD.W. The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression.Int. J. Mol. Sci.20212212656010.3390/ijms22126560 34207286
     [Google Scholar]
  184. KurykL. BertinatoL. StaniszewskaM. PancerK. WieczorekM. SalmasoS. CalicetiP. GarofaloM. From conventional therapies to immunotherapy: Melanoma treatment in review.Cancers (Basel)20201210305710.3390/cancers12103057 33092131
     [Google Scholar]
  185. ButterfieldL.H. NajjarY.G. Immunotherapy combination approaches: Mechanisms, biomarkers and clinical observations.Nat. Rev. Immunol.202424639941610.1038/s41577‑023‑00973‑8 38057451
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206365310250310081445
Loading
Unraveling the Role of Tumor-infiltrating Immune Cells in Modulating Cancer Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry 26, 12 (2026); https://doi.org/10.2174/0118715206365310250310081445
/content/journals/acamc/10.2174/0118715206365310250310081445
/content/journals/acamc/10.2174/0118715206365310250310081445
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cancer drug resistance; immune cell modulation; macrophages; myeloid-derived suppressor cells (MDSCs); tumor microenvironment; Tumor-infiltrating immune cells

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test